You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improved long-term biocompatibility of coronary stents by plasma coating process

    SBC: NANOVA INC.            Topic: NHLBI

    Improved long term biocompatibility of coronary stents by plasma coating process Abstract Drug eluting stentsDEShave been widely used to treat patients of coronary heart diseaseCHDdue to their better ability to control restenosis than bare metal stentsBMSHoweverthere is a high risk of late in stent thrombosis associated with DES after implantation in patientswhich could lead to fatal heart attack ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Molecular Detection of Tuberculosis without PCR amplification

    SBC: SCANOGEN INC.            Topic: NIAID

    Project Summary TuberculosisTBis a major global burden that killsmillion people every yearTB mostly affects developing countriesbut the rise of multi drug and extensively drug resistant strains is a global threatIn order to control and eradicate this diseaseit is imperative to have adequate tools to detect active TB in limited resource settings and point of carePOCsettingswhich is where most TB pa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Computerized Adaptive Assessment of Disease Impact

    SBC: QUALITYMETRIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This SBIR Phase II project will develop and evaluate a more practical and comprehensive approach to standardizing the self-assessment of disease-specific Health-Related Quality of Life (HRQOL) in the growing population of aging (45+ years) adults with, and at-risk of, co-morbid chronic conditions. Specifically, we propose to simplify disease impact screening (f ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Diagnostic Influenza RT-PCR Array

    SBC: AKONNI BIOSYSTEMS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Influenza viruses are highly contagious negative-sense RNA viruses cause approximately 114,000 hospitalizations and 20,000 deaths annually. Several drugs are approved by the US Food and Drug Administration (FDA) for treating influenza infections, but successful treatment depends on knowing the specific antigenic subtype and administering these drugs within the ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Immune Deficient Mosquitoes for Improved Malaria Sporozoite Vaccine Manufacture

    SBC: SANARIA INC.            Topic: NIAID

    Abstract An ideal tool for eliminating Plasmodium falciparumPfthe causative agent ofof all malaria deathswould be a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmissionSanaria has developed two effective vaccines that are phaseclinical trialsPf sporozoiteSPZvaccine that prevents Pf blood stage infection in andgtof recipients and PfSPZ Chal ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. DAT Selective Inhibitor As Cocaine Medication

    SBC: Novascreen Biosciences Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine addiction and dependency have reached pandemic levels and have become a continuing national healthcare concern. At present, no effective and safe medication is available to treat cocaine dependency and to ameliorate the underlying chemical addiction. During previous SBIR Phase I and Phase II supported work, we discovered several promising novel chemical ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. HLA Chip Product for FDA 510K Approval

    SBC: GENOMICS USA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We describe here a Phase II Competitive Renewal grant application, which will support a three year program of ASHI (American Society of Histocompatibility and Immunology) and FDA 510K review, for the HLA-Chip which we have developed over the past two years, with Phase II SBIR support. The deliverable at the end of year three of this Competitive Continuatio ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Integrated Top-Down/Bottom-Up Comprehensive Proteomics

    SBC: CALIBRANT BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Phase I: The R43 phase of this project aims to develop and demonstrate a capillary gel electrophoresis (CGE) based multidimensional protein separation platform capable of providing significant analyte concentration and extremely high resolving power for handling complex protein mixtures prior to mass spectrometry detection. In comparison with conventional SDS- ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government